Taysha Gene Therapies Inc美股招股说明书(2025-05-28版)

424B51d887492d424b5.htm424B5 TableofContents FiledPursuanttoRule424(b)(5)RegistrationNo.333-283801 Theinformationinthispreliminaryprospectussupplementisnotcompleteandmaybechanged.Thispreliminaryprospectussupplementandtheaccompanyingprospectusarenotanoffertosellthesecuritiesandarenotsolicitinganoffertobuythesecuritiesinanyjurisdictionwheretheofferorsaleisnotpermitted. SubjecttoCompletion,datedMay28,2025PRELIMINARYPROSPECTUSSUPPLEMENT (ToProspectusdatedDecember20,2024) $ SharesofCommonStock Pre-FundedWarrantstoPurchaseuptoSharesofCommonStock Weareofferingsharesofourcommonstock,parvalue$0.00001pershare,orthecommonstock and,inlieuofcommonstocktocertaininvestorsthatsochoose,pre-fundedwarrantstopurchaseuptosharesofourcommonstock.Thepurchasepriceofeachpre-fundedwarrantwillequalthepricepershareatwhichsharesofourcommonstockarebeingsoldtothepublicinthisoffering,minus$0.001,theexercise priceofeachpre-fundedwarrant.Eachpre-fundedwarrantwillbeimmediatelyexercisableforoneshareofcommonstock,subjecttothelimitationsdescribedinthesection“DescriptionofthePre-FundedWarrants—Exercisability.”Thepublicofferingpriceforeachshareofcommonstockis$.Wearealsoofferingthesharesofourcommonstockthatareissuablefromtimetotimeuponexerciseofthepre-fundedwarrants. OurcommonstockislistedonTheNasdaqGlobalSelectMarketunderthesymbol“TSHA.”ThelastreportedsalepriceofourcommonstockonTheNasdaqGlobalSelectMarketonMay27,2025was$2.605pershare.Thereisnoestablishedpublictradingmarketforthepre-fundedwarrants,andwedonotexpectamarkettodevelop.Wedonotintendtoapplyforlistingofthepre-fundedwarrantsonTheNasdaqGlobalSelectMarketoranysecuritiesexchangeornationallyrecognizedtradingsystem.Withoutanactivetradingmarket,theliquidityofthepre-fundedwarrantswillbelimited. Wearean“emerginggrowthcompany”anda“smallerreportingcompany”underapplicableSecuritiesandExchangeCommissionrulesandaresubjecttoreducedpubliccompanyreportingrequirements. See“ProspectusSupplementSummary—ImplicationsofBeinganEmergingGrowthCompanyandaSmallerReportingCompany.” Investinginourcommonstockinvolvesahighdegreeofrisk.See“RiskFactors”beginningonpageS-14ofthisprospectussupplement,page6oftheaccompanyingprospectusandundersimilarheadingsinthedocumentsincorporatedbyreferenceintothisprospectussupplementandtheaccompanyingprospectus. NeithertheSecuritiesandExchangeCommissionnoranystatesecuritiescommissionhasapprovedordisapprovedofthesesecuritiesordeterminedifthisprospectussupplementortheaccompanyingprospectusistruthfulorcomplete.Anyrepresentationtothecontraryisacriminaloffense. Per PerPre- FundedTota Share Warrantl Publicofferingprice $ $$ Underwritingdiscountsandcommissions(1) $ $$ ProceedstoTayshaGeneTherapies,Inc.,beforeexpenses $ $$ (1)See“Underwriting”foradescriptionofthecompensationpayabletotheunderwriters. Weintendtogranttheunderwritersanoptionforaperiodof30daystopurchaseuptoadditionalsharesofourcommonstockattheinitialpricetothepubliclesstheunderwritingdiscount. Theunderwritersexpecttodeliverthesharesandpre-fundedwarrantsagainstpaymentinNewYork,NewYorkonMay,2025. JefferiesBofASecuritiesPiperSandlerBarclays ProspectusSupplementdatedMay,2025 TableofContents TABLEOFCONTENTSPROSPECTUSSUPPLEMENT ABOUTTHISPROSPECTUSSUPPLEMENT S-i SPECIALNOTEREGARDINGFORWARD-LOOKINGSTATEMENTSS- iii PROSPECTUSSUPPLEMENTSUMMARYS- 1 THEOFFERINGS- 12 RISKFACTORSS- 14 USEOFPROCEEDSS- 20 DILUTIONS- 21 DESCRIPTIONOFCAPITALSTOCKS- 23 DESCRIPTIONOFTHEPRE-FUNDEDWARRANTSS-30 MATERIALU.S.FEDERALINCOMETAXCONSEQUENCESS-33 UNDERWRITINGS- 39 LEGALMATTERSS- 47 EXPERTSS- 47 WHEREYOUCANFINDMOREINFORMATIONS- 47 INCORPORATIONOFCERTAININFORMATIONBYREFERENCES-48 PROSPECTUS ABOUTTHISPROSPECTUS ii PROSPECTUSSUMMARY 1 RISKFACTORS 6 SPECIALNOTEREGARDINGFORWARD-LOOKINGSTATEMENTS 7 USEOFPROCEEDS 9 DESCRIPTIONOFCAPITALSTOCK 10 DESCRIPTIONOFDEBTSECURITIES 17 DESCRIPTIONOFWARRANTS 24 LEGALOWNERSHIPOFSECURITIES 27 PLANOFDISTRIBUTION 31 LEGALMATTERS 33 EXPERTS 33 WHEREYOUCANFINDMOREINFORMATION 33 INCORPORATIONOFCERTAININFORMATIONBYREFERENCE34 TableofContents ABOUTTHISPROSPECTUSSUPPLEMENT Thisprospectussupplementispartofa“shelf”registrationstatementonFormS-3(FileNo.333-283801)thatwefiledwiththeSecuritiesandExchangeCommission,ortheSEC,onDecember13,2024,whichwasdeclaredeffectiveonDecember20,2024.Thisdocumentisintwoparts.Thefirstpartisthisprospectussupplement,whichdescribesthespecifictermsofthisofferingofcommonstockandpre-fundedwarrantsandalsoaddstoandupdatesinformationcontainedintheaccompanyingprospectusandthedocumentsincorporatedbyreferenceherein.Thesecondpart,theaccompanyingprospectus,providesmoregeneralinformation.Generally,whenwerefertothisprospectus,wearereferringtobothpartsofthisdocumentcombined.Theinformationincludedorincorporatedbyreferenceinthisprospectussupplementalsoaddsto,updatesandchangesinformationcontainedorincorporatedbyreferenceintheaccompanyingprospectus. Beforebuyinganyofthesharesofcommonstockofferedhereby,weurgeyoutoreadcarefullythisprospectussupplementandtheaccompanyingprospectus,togetherwiththeinformationincorporatedhereinbyreferenceasdes